Sionna Therapeutics Inc., a biopharmaceutical company focused on advancing treatments for cystic fibrosis, announced positive results from Phase 1 clinical trials for its NBD1 stabilizers, SION-719 and SION-451. These trials, conducted in healthy volunteers, demonstrated that both stabilizers were generally well tolerated and achieved desired pharmacokinetic targets, supporting their potential as add-ons to current standard care or in combination with other modulators. Sionna plans to progress SION-719 into a Phase 2a proof-of-concept trial for cystic fibrosis patients and SION-451 into a Phase 1 dual combination trial, both set to commence in the latter half of 2025. The company aims to release topline data from these trials by mid-2026.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。